Enquire now
  • Description

 

A supramolecular inclusion complex of Natural Bioactive – Andrographolide (AG), extracted from the leaves of Andrographis paniculata (Kalmegh). It possesses excellent antiviral and immunomodulatory properties. It has been reported in published papers that it has antiviral properties and has inhibited the replication of SARS-CoV-2 virus by >99.9% .

What makes Bio-Immune® superior to other Andrographolide-based products?

  1. Offers significantly higher bioavailability & water solubility.
  2. Enhanced half-life of 6.38 hours
  3. Higher efficacy with lower dose.
  4. The only Andrographolide-based formula in the market that is suitable for both oral as well as pulmonary use.

Health Benefits:

  1. Supports the management of upper respiratory tract infections like viral fever symptoms - cough, cold, sore throat & upper respiratory tract infections.
  2. Boosts Immunity
  3. Hepatoprotective

 

Dosage:

  1. Oral Route: 100 mg per day Twice a day
  2. Nasal Route: 0.18 mg per spray, spray once in each nostril Twice a day

 

Studies Conducted:

  1. Anti-viral Properties - In vitro cell line study against SARS CoV2 virus [Reference: Published Paper – 1]
  2. Safety Study: [Reference: Published Paper – 2]

Bio-Immune® has been pre-clinically tested for its safety through oral & pulmonary route. Following studies have been conducted and published. 

           2.1 Acute Oral Toxicity Study

           2.2 Sub-acute Oral Toxicity Studies

           2.3 Acute Pulmonary Toxicity Study

           2.4 Sub-acute Pulmonary Toxicity Studies

  1. Pharmacokinetic Study: [Reference: Published Paper – 1]

Bio-Immune® has shown improved bioavailability, half-life & solubility properties through pharmacokinetic study. The study has been published on pharmacokinetic studies.

References - Published Papers

Molecular encapsulation of andrographolide in 2-hydroxypropyl- β-cyclodextrin cavity: synthesis, characterization, pharmacokinetic and in vitroantiviral activity analysis against SARS-CoV-2

Link: https://pubmed.ncbi.nlm.nih.gov/34395929/

The study has been published in a journal and has also been shortlisted in the research database of research articles on COVID-19 by WHO : https://pesquisa.bvsalud.org/global-literature-on-novel-coronavirus-2019-ncov/resource/pt/covidwho-1531288